Botanix Pharmaceuticals (ASX:BOT) is on track to launch its patient experience program for underarm sweating prescription, Sofdra, in the fourth quarter of the 2024 calendar year, according to a Monday filing with the Australian bourse.

The program intends to introduce Sofdra to its first commercial users for initial feedback before being rolled out to larger volumes of patients in the first quarter of 2025.

The clinical dermatology company added that it is on pace to generate first prescriptions from the sales in the coming months, followed by first refills.

Botanix's shares were up 6% in recent trade.